CONNECT WITH US:
Jul 13, 2022 15:30 JST
Source: Novotech Health Holdings Pte Ltd
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
SEOUL, S.KOREA, Jul 13, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval.
SK bioscience and GSK recently announced the successful authorization:
SK bioscience announced that 'SKYCovione(TM),' South Korea's first COVID-19 vaccine candidate adjuvanted with GSK's pandemic adjuvant has been authorized by the Korean Ministry of Food and Drug Safety (KMFDS). South Korea has become one of the few countries in the world to have both a domestically developed COVID-19 vaccine and a treatment.
SKYCovione(TM) is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine with combination of GSK's pandemic adjuvant. The development of SKYCovione(TM) has been supported by funding from the Bill & Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations (CEPI).
The results of the Phase III clinical trial, collected in 4,037 adults over 18-year-old, showed that SKYCovione(TM) induced neutralizing antibody responses, against the SARS-CoV-2 parental strain. The neutralizing antibody titres increased about 33 times compared to before the injection and were 3 times that of AstraZeneca's Vaxzevria(TM), the control vaccine used in the study, 2 weeks after the second dose.
The clinical trial was conducted in cooperation with 16 institutions, including Korea University Guro Hospital and IVI (International Vaccine Institute), a non-profit international organization.
SK bioscience will apply for authorizations at other selected regulatory agencies for distribution of SKYCovione(TM), including through the COVAX Facility and for emergency use listing (EUL) to the World Health Organization (WHO).
SKYCovione(TM) is based on recombinant protein vaccine technology which has been used for development of current vaccines including influenza, hepatitis B, and HPV. SKYCovione(TM) can be stored in normal refrigeration conditions from 2 to 8 degrees Celsius, so it is particularly suitable for use in low-income settings without the need for ultra-cold chain facilities.
The market expects that SKYCovione(TM) will accelerate securing of Korea's vaccine sovereignty and reducing dependence on vaccine imports.
Jaeyong Ahn, CEO of SK bioscience said, "The development of Korea's first COVID-19 vaccine was achieved based on the efforts of the government and members who have been working hard all day and night. We will continue to work with various global organizations based on our own research and manufacturing technologies to preemptively respond to new pandemics."
See full press release here
Dr. John Moller, CEO Novotech said, "As the lead CRO managing the Phase lll study in six APAC countries, the entire team at Novotech congratulates SK bioscience for such an outstanding clinical success and subsequent licence approval. Licence approval is the ultimate goal in clinical research and drug development and we are honoured to be part of the process of bringing new life-saving therapies to market. We look forward to working with SK bioscience on further vaccine developments in the near future."
Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Fujitsu Spain receives 9th award of the "Fundación Consejo España-Japón" (Spain-Japan Foundation)
Oct 05, 2022 14:13 JST
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Oct 04, 2022 16:44 JST
MHI Group Delivers Two Large-Capacity Centrifugal Chillers for Singapore's Marina Bay District Cooling System
Oct 04, 2022 11:58 JST
Rinnai and Toyota Start Exploring Hydrogen-Powered Cooking Methods
Oct 04, 2022 11:02 JST
Neste, Idemitsu Kosan, CHIMEI and Mitsubishi Corporation join forces to create a renewable plastics supply chain
Oct 03, 2022 17:11 JST
Rovanpera crowned youngest ever champion with TOYOTA GAZOO Racing
Oct 03, 2022 11:15 JST
Hitachi Astemo develops Steer-by-Wire prototype with advanced steering and failsafe function
Oct 03, 2022 09:30 JST
NEC Announces Progress on Environmental, Social and governance initiatives to support sustainable growth for the company and society
Sep 30, 2022 14:48 JST
Fujitsu highlights technologies to realize its vision for a sustainable world at CEATEC 2022
Sep 30, 2022 11:43 JST
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
Sep 30, 2022 11:00 JST
Dell Technologies and Fujitsu Collaborate to Accelerate Open RAN Global Adoption
Sep 30, 2022 10:41 JST
MHI: Advanced light water reactor "SRZ-1200"
Sep 29, 2022 17:55 JST
AEON and CJPT Begin Logistics Improvement in Kyushu
Sep 29, 2022 17:20 JST
NTT DOCOMO and NEC Reduce Power Consumption for 5G SA Core by an Average of 72% using AWS Graviton2, Followed by a Successful Onboarding of 5G SA Core on Hybrid Cloud
Sep 29, 2022 16:50 JST
NEC and Red Hat Expand Global Collaboration to Drive IT Modernization and Digital Transformation
Sep 29, 2022 16:23 JST
NTT DOCOMO to Add Fourth Virtualized Base Station to Open RAN Verification Environment
Sep 29, 2022 11:16 JST
NEC Launches Open RAN cloud-native virtualized software suite to extend the NEC Open Networks best of breed ecosystem
Sep 29, 2022 09:11 JST
MHI and Institut Teknologi Bandung Launch Joint R&D for Ammonia-Fired Power Generation Using Gas Turbines in Indonesia
Sep 28, 2022 16:05 JST
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Sep 28, 2022 15:15 JST
NEC Launches North American Innovation Hub for Open RAN
Sep 28, 2022 14:50 JST
More Latest Release >>
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference
September 15 2022 17:00 JST
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC
September 05 2022 18:00 JST
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report
September 02 2022 14:00 JST
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022"
July 25 2022 09:00 JST
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"
July 18 2022 16:00 JST
Novotech Receives "Best Biologics CRO Award 2022" at Korea Bioprocessing Excellence Awards 2022
June 29 2022 07:00 JST
Novotech Receives CRO Leadership Award for Exceeding Customer Expectations
June 23 2022 08:00 JST
SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development
June 15 2022 08:30 JST
Novotech's APAC and USA Leadership Teams at BIO 2022
June 14 2022 22:00 JST
Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China
June 06 2022 18:00 JST
More Press release >>